EMBC EMBECTA CORP

Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes

Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes

FREMONT, Calif. and PARSIPPANY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Intuity Medical, Inc. and Embecta Corp. (“embecta”) (NASDAQ: EMBC) today announced they have signed a co-promotional agreement under which embecta sales representatives will be able to promote Intuity Medical’s innovative POGO Automatic® Blood Glucose Monitoring System to healthcare professionals they call on within the U.S., effective immediately.

Both companies are dedicated to improving the lives of people with diabetes. Having spun off from BD (Becton, Dickinson and Company) in April of this year, embecta is one of the world’s largest pure-play diabetes companies and, with a nearly 100-year history of leadership in insulin delivery, well established across the U.S. market. Intuity Medical is a medical technology company focused on the development and commercialization of seamless and intuitive blood glucose monitoring solutions.

“We are excited to partner with an established leader like embecta that has such extensive experience serving people with diabetes,” said George Zamanakos, President and CEO of Intuity Medical. “Working closely with the embecta team will help us expand where we’re able to offer POGO Automatic, giving a new option for simplifying diabetes to millions of people currently relying on conventional blood glucose meters.”

With its 10-test cartridge technology, POGO Automatic is the only FDA-cleared automatic blood glucose monitor (ABGM) that lances, collects blood, and produces a glucose result at the push of one button, ending the need to individually load and then dispose of lancets and test strips. Being able to offer POGO Automatic will expand the innovation and breadth of embecta’s diabetes care offerings.

“The agreement to promote POGO Automatic to healthcare professionals not only enables us to expand our offerings to physicians we call on, but it does so within an innovative new category,” said Tom Blount, Senior Vice President and President, North America, for embecta. “Automatic blood glucose monitoring is transforming this vital aspect of self-management into something truly seamless and simple for people with diabetes.”

About Intuity Medical, Inc.

Intuity Medical, Inc. is a commercial-stage medical technology company focused on developing innovative solutions to improve the health and quality of life of people with diabetes. Headquartered in Fremont, California, the company strives to simplify diabetes management and was founded with the mission of making life with diabetes easier. Intuity Medical’s POGO Automatic® Blood Glucose Monitoring System is the only FDA-cleared automatic blood glucose monitoring system that lances and collects blood in just one step with 10-test cartridge technology, ending the need to individually load lancets and test strips (as required by conventional blood glucose meters). POGO Automatic delivers a much simplified and discreet blood glucose testing experience that is less disruptive to the everyday lives of people with diabetes. To learn more, please visit .

About embecta

embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit .

CONTACTS

Media (for Intuity Medical):

Jeff Christensen

831-566-0275

Media (for embecta):

Christian Glazar

Sr. Director, Corporate Communications

908-821-6922

 

embecta Investors:

Pravesh Khandelwal

VP, Head of Investor Relations

551-264-6547

A photo accompanying this announcement is available at



EN
07/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EMBECTA CORP

 PRESS RELEASE

embecta to Participate in Investor Events

embecta to Participate in Investor Events PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2025 Wells Fargo Healthcare Conference Management will host a fireside session on Thursday, September 4, 2025, at 3:00 p.m. EDT and one-on-one investor meetings throughout the day at the Encore Boston Harbor Hotel, Boston. 2025 Morgan Stanley 23rd ...

 PRESS RELEASE

Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025. "Q3 was a strong quarter for embecta, reflecting solid commercial execution, aided in part by the timing of customer orders. Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are ti...

 PRESS RELEASE

embecta Announces Quarterly Cash Dividend

embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innova...

 PRESS RELEASE

embecta to Report Fiscal Third Quarter 2025 Financial Results

embecta to Report Fiscal Third Quarter 2025 Financial Results PARSIPPANY, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal third quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, August 8, 2025. Those who would like to participate may access the live webcast , or access the teleconference ....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch